Incidence of diabetes mellitus-related comorbidities among patients attending two major HIV clinics in Botswana: a 12-year retrospective cohort study

• Published in: BMC research notes 2018-02, Vol.11 (1), p.90-90, Article 90
• Main Authors: Rankgoane-Pono, Goabaone, Tshikuka, Jose Gaby, Magafu, Mgaywa Gilbert Mjungu Damas, Masupe, Tiny, Molefi, Mooketsi, Hamda, Shimeles Genna, Setlhare, Vincent, Tapera, Roy, Mbongwe, Bontle
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; AIDS; Analysis; Antiretroviral therapy; Botswana; Cohort analysis; Combination antiretroviral therapy; Comorbidity; Complications and side effects; Data collection; Development and progression; Diabetes; Diabetes mellitus; Diabetes-related comorbidities; Distribution; Drug therapy; Health aspects; Highly active antiretroviral therapy; HIV; HIV carriers; Human immunodeficiency virus; Incidence; Medical records; Patients; PLHIV; Research Note; Sample size; Survival; Survival analysis; Type 2 diabetes
• ISSN: 1756-0500; 1756-0500
• DOI: 10.1186/s13104-018-3144-9

Exposure to combination antiretroviral therapy (cART) is associated with the development of diabetes mellitus related comorbidities (DRCs). This study aims to: (i) estimate the incidence of DRCs among cART recipients, (ii) assess the time-to-event (development of DRC) and, (iii) compare survival function between recipients on first-line regimen and those on second-, third-line cART regimen. The incidence of DRCs was 26.8/1000 person-years, with total time of exposure of 3316 person-years. The average time to event for all the three regimens was 11.72 ± 0.20 years. The first-line cART regimen had a shorter mean ± SE of 10.59 ± 0.26 years to the event compared to 12.69 ± 0.24 years for the second-, third-line cART regimen. Recipients on the first-line had a shorter survival than recipients on second-, third-line cART (Log-rank X  = 8.98, p